T1	intervention 0 9	Nebivolol
T2	condition 20 54	doxorubicin-induced cardiotoxicity
T3	No-of-participants 258 260	60
T4	average-age 277 290	52.6Â±13 years
T5	eligibility 292 373	with HER2 negative breast cancer, scheduled to undergo treatment with doxorubicin
T6	intervention-participants 450 452	30
T7	control 536 549	control group
T8	control-participants 553 555	30
T9	outcome-Measure 769 785	Echocardiography
T10	outcome 933 983	baseline clinical and echocardiographic parameters
T11	outcome 1061 1065	died
T12	outcome 1105 1113	withdrew
T13	outcome 1178 1264	left ventricular (LV) ejection fraction, shortening fraction, and LV diameters changed
T14	outcome 1289 1326	Tissue Doppler imaging (TDI) detected
